## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 12b-25

SEC FILE NUMBER
001-13341

CUSIP NUMBER 888314705

## NOTIFICATION OF LATE FILING

(Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form	orm 11-K ☑ Form 10-Q ☐ Form 10-D ☐ Form N-CEN	☐ Form N-CSR
For Period Ended: September 30,	2024	
Nothing in this form shall be o	construed to imply that the Commission has verified an	y information contained herein.
If the notification relates to a portion of the filing checked a	bove, identify the Item(s) to which the notification relates	:
	PART I — REGISTRANT INFORMATION	
	Titan Pharmaceuticals, Inc.	
	Full Name of Registrant	
	Former Name of Registrant (If Applicable)	
	10 Fast 53 <sup>rd</sup> Street, Suite 3001	
	10 East 53 <sup>rd</sup> Street, Suite 3001 Address of Principal Executive Office (Street and Number	r)
	Navy Voyle, NV 10022	
	New York, NY 10022 City, State and Zip Code	
(b) The subject annual report, semi-annual rebe filed on or before the fifteenth calend distribution report on Form 10-D, or port	I in Part III of this form could not be eliminated without un eport, transition report on Form 10-K, Form 20-F, Form 1	nreasonable effort or expense; 11-K, Form N-CEN or Form N-CSR, or portion thereof, wil quarterly report or transition report on Form 10-Q or subjecty by following the prescribed due date; and
State below in reasonable detail why Forms 10-K, 20-F, 11 time period.		or portion thereof, could not be filed within the prescribed
Titan Pharmaceuticals, Inc. ("we" or "our") is unable unreasonable effort or expense due to delays in obtaining the fifth calendar day following its original prescribed d	ng and compiling information for inclusion in the Repo	
	PART IV — OTHER INFORMATION	
(1) Name and telephone number of person to contact in reg	gard to this notification	
Brynner Chiam	(786)	769-7512
(Name)	(Area Code)	(Telephone Number)
	13 or 15(d) of the Securities Exchange Act of 1934 or Se registrant was required to file such report(s) been filed? I	ection 30 of the Investment Company Act of 1940 during the f answer is no, identify report(s).   Yes  No
(3) Is it anticipated that any significant change in results included in the subject report or portion thereof? $\square$ Ye		fiscal year will be reflected by the earnings statements to b
If so, attach an explanation of the anticipated change, both i	narratively and quantitatively, and, if appropriate, state the	e reasons why a reasonable estimate of the results cannot be

There has been no significant change as between the three months ended September 30, 2024 and the three months ended September 30, 2023 reflected by the

made.

earnings statements to be included in the Report.

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date November 15, 2024

/s/ Brynner Chiam
Name: Brynner Chiam
Title: Director